• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Johnson & Johnson's Price Strength Is Ripping the Band-Aid Off This Rally

Long-time investors in JNJ are probably not surprised how well the stock has responded in the past few weeks.
By BRUCE KAMICH
Apr 14, 2020 | 10:06 AM EDT
Stocks quotes in this article: JNJ

Johnson & Johnson (JNJ) reported their Q1 numbers this morning. They posted a Non-GAAP EPS of $2.30 which is $0.30 higher than estimates, and GAAP EPS of $2.17 beat by $0.74. Revenue was reported at $20.69 billion (+3.3% Y/Y) which beats estimates by $1.21 billion.

Let's check the charts of this member of the Dow Jones Industrial Average (DJIA).

In this daily bar chart of JNJ, below, we can see while the selloff lasted longer than other companies in that it started in early February and ran to late March... the rebound has been stellar.

Prices have retraced most of the decline and are trading above the bottoming 50-day moving average line and the bottoming 200-day moving average line. Few stocks that I have reviewed can say that.

The daily On-Balance-Volume (OBV) line has been slow to respond on the upside but the Moving Average Convergence Divergence (MACD) is now close to crossing back above the zero line for an outright go long signal. 

 

In this weekly bar chart of JNJ, below, we can see that prices briefly broke the lows of the past few years. This is interesting as it is not the typical response as investors seem to have rushed in to take advantage of these temporary bargains.

Prices are back above the declining 40-week moving average line. The weekly OBV line has responded quickly and is back near its best levels. A new high for the OBV line will confirm and foreshadow future gains in JNJ. The MACD oscillator has narrowed and is now close to a new outright go long signal.  

 

In this daily Point and Figure chart of JNJ, below, we can see that a trade at $153.96 will be a new high for the move up and this breakout should precipitate further gains. A potential price target of $183 is being projected. 

 

Bottom line strategy: Long-time investors in JNJ are probably not surprised how well the stock has responded in the past few weeks. Traders and investors can continue to approach JNJ from the long side risking a close below $130. The $175-$183 area is our initial price objective.  

(Johnson & Johnson is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells JNJ? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Earnings | Investing | Markets | Stocks | Technical Analysis | Trading | Health Care Equipment & Services | Healthcare | Pharmaceuticals | Coronavirus

More from Investing

Stock Market Continues to Defy Conventional Wisdom

James "Rev Shark" DePorre
Jan 22, 2021 5:04 PM EST

Concerns about the action being overheated remain, but rotational action keeps the momentum going.

AMC Is a High Risk, High Reward Play

Timothy Collins
Jan 22, 2021 2:15 PM EST

Short and sweet: This is based on the high running emotions of the markets. There's little to it beyond that.

GoodRx Needs a Shot in the Arm to Improve Its Outlook

Bruce Kamich
Jan 22, 2021 2:03 PM EST

IPOs in recent months have done extremely well -- not so GDRX.

2021 and 2022 Look Difficult for Intel, While 2023 -- Might -- Be Better

Eric Jhonsa
Jan 22, 2021 1:44 PM EST

Competition from AMD and ARM CPU developers looks set to take a toll over the next two years. But Intel could be in better shape in 2023 if its new CEO is ready to make some tough choices.

GameStop and the Dangerous Game of Gamma Squeezes

Timothy Collins
Jan 22, 2021 1:26 PM EST

What happened after Citron Research posted a video about GameStop is very troubling.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    I'll discuss price targets in my Saturday column.
  • 07:54 AM EST GARY BERMAN

    Friday Morning Fibocall for 1/22/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login